These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12494208)

  • 21. [Effect of imidazoline receptor agonist moxonidine on the state of microcirculation and renal function in patients with hypertension and diabetes mellitus type 2].
    Trusov VV; Aksenov KV
    Kardiologiia; 2003; 43(9):44-8. PubMed ID: 14682297
    [No Abstract]   [Full Text] [Related]  

  • 22. [ACE-dependent and sympathetic components of blood pressure regulation in patients with essential hypertension].
    Aparina TV; Gomazkov OA; Dilakian EA; Britov AN
    Vopr Med Khim; 2001; 47(4):411-8. PubMed ID: 11693029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Renoprotecion With Metabolic Syndrome: the Possibility of Receptor Agonist Imidazoline Moxonidine].
    Ostroumova OD; Zykova AA
    Kardiologiia; 2016 Oct; 56(10):72-79. PubMed ID: 28290898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moxonidine: a review of its use in essential hypertension.
    Fenton C; Keating GM; Lyseng-Williamson KA
    Drugs; 2006; 66(4):477-96. PubMed ID: 16597164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Imidazol receptor agonists--new possibilities for treating hypertension].
    Nowicki M; Wiecek A; Chudek J
    Postepy Hig Med Dosw; 1995; 49(5):631-43. PubMed ID: 8677226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Moxonidine for hypertension.
    Drug Ther Bull; 1997 May; 35(5):33-6. PubMed ID: 9282418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Imidazole receptors and blood pressure regulation. High receptor selectivity of moxonidine].
    Molderings GJ; Göthert M; Christen O; Schäfer SG
    Dtsch Med Wochenschr; 1993 Jun; 118(25):953-8. PubMed ID: 8100191
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety and efficacy of moxonidine in mild to moderate hypertension.
    Jain S; Malhotra P; Kumari S; Varma S
    J Assoc Physicians India; 2001 Aug; 49():829-30. PubMed ID: 11837474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Moxonidine: a review of safety and tolerability after seven years of clinical experience.
    Schachter M
    J Hypertens Suppl; 1999 Aug; 17(3):S37-9. PubMed ID: 10489097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imidazoline receptors associated with noradrenergic terminals in the rostral ventrolateral medulla mediate the hypotensive responses of moxonidine but not clonidine.
    Chan CK; Burke SL; Zhu H; Piletz JE; Head GA
    Neuroscience; 2005; 132(4):991-1007. PubMed ID: 15857704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical pharmacology of hypotensive drugs acting on central imidazoline receptors].
    Drzewoski J; Wiśniewska-Jarosińska M
    Pol Arch Med Wewn; 1998 Dec; 100(6):561-9. PubMed ID: 10405570
    [No Abstract]   [Full Text] [Related]  

  • 32. [Imidazole receptor agonists--a new advance in the treatment of hypertension?].
    Spinar J; Vítovec J
    Vnitr Lek; 2000 Feb; 46(2):122-5. PubMed ID: 11048538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Imidazoline receptors and use of drug blocking receptors I1].
    Lada W
    Pol Merkur Lekarski; 1996 Aug; 1(2):124-5. PubMed ID: 9156911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of moxonidine in elderly patients with resistant hypertension.
    Martin U; Hill C; O' Mahony D
    J Clin Pharm Ther; 2005 Oct; 30(5):433-7. PubMed ID: 16164488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of I1 imidazoline receptors in the sympathoinhibition produced by intracisternally administered rilmenidine and moxonidine.
    Szabo B; Urban R
    Arzneimittelforschung; 1997 Sep; 47(9):1009-15. PubMed ID: 9342413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [On the therapy of hypertension with an imidazoline derivative].
    Krause W; Krämer D; Grünitz B
    Med Klin; 1969 Jul; 64(28):1274-6. PubMed ID: 5799785
    [No Abstract]   [Full Text] [Related]  

  • 37. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
    Sharma AM; Wagner T; Marsalek P
    J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imidazoline Receptors: A Novel Approach to Hypertension--the Contribution of Rilmenidine. Symposium proceedings. Milan, Italy, June 8, 1993.
    Am J Cardiol; 1994 Dec; 74(13):1A-65A. PubMed ID: 7998579
    [No Abstract]   [Full Text] [Related]  

  • 39. Selective imidazoline receptor agonists and lipid metabolism.
    Elisaf M; Tselepis A; Siamopoulos K
    Clin Chem Lab Med; 1999 Feb; 37(2):165. PubMed ID: 10219506
    [No Abstract]   [Full Text] [Related]  

  • 40. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites.
    Ernsberger P; Damon TH; Graff LM; Schäfer SG; Christen MO
    J Pharmacol Exp Ther; 1993 Jan; 264(1):172-82. PubMed ID: 8380858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.